Skip to main content

Table 1 Preoperative demographic and clinical characteristics according to whether osteoporosis was primary or glucocorticoid-induced

From: Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study

 

Total

Primary

GIOP

p-value

Cases, n

159

132

27

–

Age at time of surgery (years)

75.6 ± 6.7

76.6 ± 6.4

71.0 ± 6.1

0.001

Sex (male)

136 (85.5%)

111 (84.1%)

25 (92.6%)

0.37

BMI

22.3 ± 5.1

22.4 ± 4.7

22.3 ± 6.4

0.92

Smoking history (yes/no)

20 (12.6%)

19 (14.4%)

1 (3.7%)

0.20

Number of previous vertebral fracture

0.5 ± 0.9

0.4 ± 0.9

0.7 ± 1.2

0.20

Number of new vertebral fracture

1.1 ± 0.2

1.1 ± 0.2

1.1 ± 0.3

0.79

Time from injury to surgery (days)

173 ± 240

169 ± 251

192 ± 184

0.65

BMD (YAM%)

71.0 ± 16.1

70.4 ± 14.5

73.5 ± 16.4

0.55

Preoperative use of osteoporosis medication

71 (44.7%)

49 (37.1%)

22 (81.5%)

< 0.001

 BP

55 (34.6%)

41 (31.1%)

14 (51.9%)

0.047

 Vit D

14 (8.8%)

7 (5.3%)

7 (25.9%)

0.003

 TP

7 (4.4%)

4 (3.0%)

3 (11.1%)

0.10

Number of fixed level

3.1 ± 0.8

3.1 ± 0.8

3.0 ± 0.9

0.53

Preoperative JOA score

4.2 ± 3.4

4.3 ± 3.3

3.4 ± 3.9

0.27

Preoperative VAS (back pain)

71.5 ± 24.4

70.7 ± 24.3

75.3 ± 24.9

0.39

Preoperative VAS (leg pain or numbness)

55.0 ± 31.7

55.0 ± 31.9

54.7 ± 31.5

0.696

  1. GIOP glucocorticoid-induced osteoporosis, BMI body mass index, BMD bone mineral density, YAM young adult mean, BP bisphosphonate, Vit D vitamin D, TP teriparatide, JOA Japan Orthopaedic Association, VAS visual analogue scale